| Literature DB >> 21898179 |
Edyta Reszka1, Ewa Jablonska, Jolanta Gromadzinska, Wojciech Wasowicz.
Abstract
The most commonly used methods for assessing the selenium (Se) status in humans involve analysis of Se concentration, selenoprotein activity, and concentration in the blood and its compartments. Recently, it has been suggested that the expression of selenoprotein mRNA in circulating blood leukocytes could differently reflect Se status, due to prioritization of specific selenoprotein synthesis in response to dietary Se supply. Whereas the Se levels required for optimization of selenoprotein P level and plasma glutathione peroxidise activity are well known, estimation of Se level that is required for maximal mRNA expression of selenoprotein in humans is the subject of current investigations. Studies on rats suggest that whole blood selenoprotein mRNA level can be used as the relevant molecular biomarker for assessing Se status, and suboptimal Se intake may be sufficient to achieve effective expression. Human studies, however, did not confirm this hypothesis. According to studies on rodents and humans discussed in this review, it appears that suboptimal Se intake may be sufficient to satisfy molecular requirements of Se and it is lower than current recommended dietary intake in humans. The use of selenoprotein transcripts as a molecular biomarker of Se status requires further studies on a large group of healthy individuals with different baseline Se, including data regarding genetic polymorphism of selenoproteins and data regarding potential modifiers of Se metabolism.Entities:
Year: 2011 PMID: 21898179 PMCID: PMC3316749 DOI: 10.1007/s12263-011-0246-6
Source DB: PubMed Journal: Genes Nutr ISSN: 1555-8932 Impact factor: 5.523
Human selenoproteins
| Function | Abbreviations | Selenoprotein | Cellular; tissue localization |
|---|---|---|---|
| Antioxidant enzymes | GPx1a | Cytosolic glutathione peroxidase (GPx) | Cytosol, mitochondria; widely expressed |
| GPx2a | Gastrointestinal GPx | Cytosol, ER; gastrointestinal tissue, liver | |
| GPx3 | Plasma GPx | Secreted; plasma, extracellular fluid, liver, kidney, heart, lung, thyroid, gastrointestinal tissue, breast | |
| GPx4a | Phospholipid hydroperoxide GPx | Cytosol, mitochondria, nucleus; widely expressed, testes | |
| GPx6 | Olfactory GPx | Unknown; embryo and oilfactory epithelium | |
| SelK | Selenoprotein K | ER, membrane protein | |
| SelR | Selenoprotein R; methionine sulfoxide reductase B1 | Cytosol, nucleus; widely expressed | |
| SelW | Selenoprotein W | Cytosol; widely expressed, brain, colon, heart, skeletal muscle, prostate | |
| Transport and storage of Se | SepP1a | Selenoprotein P | Secreted, cytosol; plasma, widely expressed, brain, liver, testes |
| Redox signaling | TrxR1a | Thioredoxin reductase, type I | Cytosol, nucleus; widely distributed |
| TrxR2 | Thioredoxin reductase, type II | Mitochondria; widely distributed | |
| TrxR3 | Thioredoxin reductase, type III | Cytosol, ER, nucleus; testis-specific | |
| Thyroid hormone metabolism | DIO1 | Iodothyronine deiodinase, type I | Membrane protein; kidney, liver, thyroid, brown adipose tissue |
| DIO2 | Iodothyronine deiodinase, type II | ER, membrane protein; thyroid, central nervous system, brown adipose tissue, skeletal muscle | |
| DIO3 | Iodothyronine deiodinase, type III | Membrane protein; placenta, central nervous system, fetus | |
| Protein folding | Sep15a | Selenoprotein 15 kDa | ER lumen |
| SelN | Selenoprotein N | ER membrane; widely expressed | |
| SelM | Selenoprotein M | ER lumen | |
| SelSa,b | Selenoprotein S | ER, membrane protein; widely expressed | |
| Sec synthesis | SPS2 | Selenophosphate synthetase | Cytosol |
| Unknown | SelH | Selenoprotein H | Nucleus; widely expressed |
| SelI | Selenoprotein I | Transmembrane | |
| SelO | Selenoprotein O | Unknown | |
| SelT | Selenoprotein T | ER membrane | |
| SelV | Selenoprotein V | Testes |
Adapted from Papp et al. (2007), Shchedrina et al. (2010), Fairweather-Tait et al. (2010)
aGenetic polymorphism associated with cancer
bInflammatory disease
Human studies on selenoprotein molecular biomarkers
| Study | Baseline daily Se intake (μg) | Baseline plasma Se level (ng/ml) | Selenoprotein gene expression in WBC |
|---|---|---|---|
| UK, SELGEN study, | Not presented | 93.9 ± 1.7 | Lymphocyte Up-regulation:
|
| Denmark, | 49.8 ± 13.6 | 113.2 ± 12.2 | Leukocyte No effect: |
| Denmark, PRECISE pilot study, | 49.8 ± 13.6 | 93 ± 11.2 | Leukocyte No effect: |
| UK, | 48 ± 14 | 89.2 ± 12.5 | Whole blood No effect and no association between Se status and |
| Poland, | 24.2 ± 17.4 (unpublished data) | 54.3 ± 14.6 | Leukocyte No association between Se status and |
Fig. 1Correlation between plasma Se and GPx3 transcripts level in population with adequate—British (whole blood) (Sunde et al. 2008) (a) and suboptimal—Polish (leukocyte) (Reszka et al. 2009) (c) Se level and correlation between plasma Se level and SePP1 transcripts level in population with adequate—British (whole blood) (b) and suboptimal—Polish (leukocyte) (d) Se level a and b reproduced with permission from Sunde et al. (2008)
Fig. 2Biomarkers of selenium status in humans. A scheme of traditional and molecular biomarkers measurements with the impact of potential modifiers (physiological, environmental, genetic). The optimal selenium biomarker should reflect all putative egzo- and endogenous factors which can modulate selenium bioavailability, metabolism and selenoprotein transcription, biosynthesis, transport, activity and function. A type of measurement used for the determination of selenium status should be also considered